ISPOR EUROPE 2025
9-12 November, Glasgow, Scotland, UK
Join EVERSANA and global healthcare leaders as they convene at ISPOR Europe 2025, the leading global conference for Health Economics and Outcomes Research (HEOR).
Our Value & Evidence, Data & Analytics and NAVLIN by EVESANA’s HTA and Pricing & Access experts will be onsite to discuss how we use a variety of analytics, evidence generation, and evidence synthesis activities to help support market access and reimbursement for pharmaceutical and medical devices.
Schedule a meeting with one of our experts to discuss your business needs and visit us in Booth #304.
Don’t Miss Our Featured Workshops
-
Optimal Strategies for Predicting and Consolidating PICOs: One Best Method or a Blended Approach?
Tuesday, 11 November | 17:00 – 18:00
Moderator: Pamela Vo, Vice President, HEOR, EVERSANA, Basel, Switzerland
Speakers: Niklas Hedberg, MSc Sweden’s Dental and Pharmaceuticals Benefits Agency (TLV); Zsombor Zrubka, MBA, PhD, MD, Óbuda University, Budapest, Hungary; Michael Happich, DrPH, PhD, Eli Lilly, Bad Homburg, GermanyDuring this session, panelists will discuss:
- The complexity of defining PICOs (Population, Intervention, Comparator, Outcome) for EU Joint Clinical Assessment (JCA), due to input from all 27 Member States and the resulting volume of literature.
- The challenge of predicting and consolidating PICOs that reflect both shared and local priorities across the EU.
- Exploration of alternative approaches to streamline PICO development:
- Country surveys for national specificity.
- AI-driven PICO prediction using retrospective HTA and clinical data.
- Traditional SLRs (systematic literature reviews) as a foundational but resource-intensive method.
- Debate over whether a single optimal method or a blended, tailored approach is most effective for PICO development.
- The goal to make evidence gathering more efficient, reduce duplication, and support coordinated decision-making in the evolving EU HTA framework.
EVERSANA’s 2025 Poster Presentations
Monday, 10 November | Poster Session 1
- PT3: Radiographic Progression-Free Survival (rPFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line (1L) Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Meta-Analysis and Surrogate Threshold Effect
- HTA56: Beyond the Surface: Health Technology Assessment and Reimbursement for Inflammatory or Autoimmune Disorders With Cosmetic and Dermatological Manifestations
- EE44: All-Cause Healthcare Resource Use in Recurrent Respiratory Papillomatosis: A Claims-Based Comparison With Matched Controls
- EE207: Cost-Utility Analysis of Intermittently Scanned Continuous Glucose Monitoring in Individuals with Type 1 Diabetes in Sweden – A National Real-World Evidence Perspective
- EE208: Cost-Effectiveness Analysis of Intermittently Scanned Continuous Glucose Monitoring in Individuals With Type 2 Diabetes Using Insulin in Sweden: A National Real-World Evidence Perspective
Monday, 10 November | Poster Session 2
- CO57: Comparative Efficacy of First-Line (1L) Therapies for Patients With Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC): An Updated Systematic Literature Review (SLR) and Bayesian Network Meta-Analyses (NMAs)
- EE200: Cost-Effectiveness Analysis of FreeStyle Libre Systems vs. Self-Monitoring of Blood Glucose in People With Type 2 Diabetes on Basal Insulin: An Israeli Healthcare System Perspective
Tuesday, 11 November | Poster Session 3
- PCR148: Listening to the Voice of the Patient: Insights From a Survey on the Burden of Recurrent Respiratory Papillomatosis in the United States
- EE326: Development and Validation of a Novel Patient Microsimulation Cost-Effectiveness Model to Evaluate Automated Insulin Delivery Systems in Type 2 Diabetes
Tuesday, 11 November | Poster Session 4
- HTA271: Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis
- HTA229: Maximizing Acceptance of Patient-Reported Outcome Data in German HTA Decision Making: Results From a Horizon Scan
- CO162: Matching-Adjusted Indirect Comparison Between Garadacimab and Donidalorsen for Long Term Prophylaxis in Hereditary Angioedema
Wednesday, 12 November | Poster Session 5
- CO230: Systematic Review of Prognostic Factors and Treatment Effect Modifiers for Transthyretin Amyloid Cardiomyopathy
- SA91: Targeted Literature Review Examining the Inclusion of Caregiver Costs and Quality of Life in Published Economic Models for Neurological Conditions
- EE682: Targeted Literature Review Informing Economic Model Structures in Atherosclerotic Cardiovascular Disease
Our Latest Insights on Key Industry Topics
Check out our latest article authored by our team of experts or explore our library of publications to learn more about our RWE/HEOR efforts.